Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | POLB | P06746 | 7/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21955417 | 0.93 | KMT2A (0.54) | MAPTPOLBKMT2AMEN1KDM4E | |
| SCHEMBL25839451 | 0.79 | MAPT (0.53) | MAPTPOLBKMT2AMEN1KDM4E | |
| SCHEMBL23544870 | 0.78 | KDM4E (0.56) | MAPTPOLBKDM4ECYP2C9CYP2C19 | |
| SCHEMBL21955418 | 0.78 | MAPT (0.58) | MAPTPOLBKMT2AKDM4ECYP2C19 | |
| SCHEMBL2767991 | 0.76 | ME2 (0.58) | MAPTPOLBKMT2AKDM4ECYP2C9 | |
| SCHEMBL25443711 | 0.76 | POLB (0.55) | MAPTPOLBKMT2AMEN1KDM4E | |
| SCHEMBL21876102 | 0.75 | CKS1B (0.49) | MAPTPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL25840501 | 0.75 | MAPT (0.64) | MAPTPOLBKMT2AMEN1KDM4E | |
| SCHEMBL14444869 | 0.75 | KDM4E (0.75) | MAPTKMT2AMEN1KDM4ECYP2C9 | |
| SCHEMBL2766451 | 0.73 | POLB (0.67) | MAPTPOLBKMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | MAPT 4071/4885POLB 3964/4885KMT2A 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.